Sutro Biopharma, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders-approved the election of three Class II directors and the appointment of Ernst & Young LLP as the company's independent registered public accounting firm. Additionally, the meeting held a voting on a non-binding advisory basis, voting to approve the compensation of the company's named executive officers.
